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ABSTRACT  
 
Objective: The objective of this selective EBM review is to determine whether or not curcumin, 
whether alone or in conjunction with alternative therapy, has an effect on Major Depressive 
Disorder (MDD).  
 
Study Design: Systematic review of 3 primary studies, published between 2013 and 2016.  
 
Data Sources: Three randomized control trials (RCT), two of which were double blind. These 
studies were found using Cochrane Systematic Reviews and PubMed.  
 
Outcomes Measured: Outcome for all three articles are symptomatic changes of MDD. The 
outcomes measured were Patient-Oriented Evidence that Matters (POEMS) and were assessed 
using various self-rated tools.   
 
Results: All three studies demonstrated an improvement in depressive symptoms compared to 
placebo or other control groups. In Lopresti, Maes et al., curcumin has a significant effect on 
symptoms compared to placebo (p=0.045).1 In Sanmukhani et al., an improvement was seen in 
the group receiving curcumin, although not statistically significant (p=0.58).2 Lastly, Lopresti, 
Drummond compared placebo to low-dose curcumin, high-dose curcumin, and low-dose 
curcumin combined with saffron. In this study, drug treatment with curcumin had a positive 
effect on patients with depression (p=0.012), although there was no difference between the 
differing curcumin doses or curcumin/saffron combination.3 
 
Conclusions: Curcumin does appear to be safe and effective for adults suffering from MDD. 
Two out of the three trials included in this systematic review were able to show significant data 
in support of the positive effects of curcumin. The use of curcumin for symptomatic relief in 
MDD is promising, however, more RCT must be done to support this.  
 
Keywords: curcumin, depression, major depressive disorder 
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INTRODUCTION 
Major depressive disorder is a mental health condition that is characterized by chronic 
depressed mood and/or loss of interest in activities and hobbies. Oftentimes, there may be 
accompanying low self-esteem, decreased energy, fatigue, and non-specific pain. It was initially 
thought that a disturbance is in the level of serotonin was the major cause of MDD, however, it is 
now known that there are many other dysregulations that contribute, such as, dysregulation in the 
hypothalamic-pituitary-adrenal axis, activation of immune-inflammatory pathways, 
mitochondrial dysfunction, and neuroprogression.1  
MDD affects individuals worldwide and is a cause of impaired functional capacity which can 
lead to suicides.2 It affects approximately 6-8 percent of adults each year with a lifetime 
prevalence of 15-20%.3 Because MDD is only a small aspect of mental health disorders, there is 
not an exact number of yearly healthcare visits. However, according to the CDC, the percent of 
physician office visits with depression indicated on the medical record is 10.4%, It is estimated 
that a total of $210.5 billion are spent per year for MDD patients.4, 5  
There are several traditional methods that are used to treat MDD. Specific prescription 
medications include, selective serotonin reuptake inhibitors (SSRIs), serotonin and 
norepinephrine reuptake inhibitors (SNRIs), dopamine reuptake blockers, and tricyclic 
antidepressants. Cognitive behavioral therapy and electroconvulsive therapy is sometimes used 
in conjunction. Because the disease is chronic, patients must be on long term treatment, however, 
pharmacological therapy has significant adverse reactions and side effects. Additionally, some 
patients may be resistant to these medications. Therefore, a safer alternative is being searched 
for.2 Curcumin is the major active ingredient in turmeric (Curcuma longa), which often used as a 
southeast Asian cooking spice. It is a potent antioxidant that can lower markers of antioxidant 
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stress, act as a COX-2 inhibitor, and lower pro-inflammatory cytokines.1 Additionally, it can 
affect the hypothalamic-pituitary-adrenal axis and influence monoamine transmission through its 
effects on serotonergic and dopaminergic activity.1  
 
OBJECTIVE 
 The objective of this selective EBM review is to determine “what are the effects of 
curcumin, whether alone or in conjunction with alternative therapy, on major depressive 
disorder?”  
 
METHODS 
 This selective EBM review analyzed 3 randomized control studies that evaluated the 
aforementioned objective. The population criteria included males and females over the age of 18 
who are suffering from MDD. All three RTCs used curcumin as the main intervention compared 
to placebo or another control group. Two of the three trials (Lopresti, Drummond and 
Sanmukhani et al.) had multiple arms in their studies and further evaluated the combination of 
curcumin with other therapy options. The outcomes measured in all three RTCs were 
symptomatic changes of MDD using various self-rating tools such as, Inventory of Depressive 
Symptomatology self-rated score (IDS-SR30 score), Spielberger State-Trait Anxiety Inventory 
tool (STAI tool), and Hamilton Depression Rating Scale (HAM-D17 scale).  
 Keywords used to search for the articles included, “curcumin”, “depression”, and “major 
depressive disorder”. All articles were found on PubMed and published in the English language. 
Types of studies searched included only RTCs that were POEMs, included human species data, 
and originally published in a peer reviewed journal within the last 10 years. Any studies that 
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were found on the Cochrane database or previously published by a student were excluded. Other 
exclusion criteria included patients not suffering from MDD or were being evaluated for MDD 
and another concurrent disease. Summary of statistics used were relative risk reduction (RRR), 
absolute benefit increase (ABI), numbers needed to treat (NNT), p-value, and ANOVA F-score. 
The demographics and characteristics of the individuals included in these studies are displayed in 
Table 1.  
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Table 1: Demographics & Characteristics of Included Studies 
 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Lopresti, 
Drummond3 
(2016) 
Randomized 
Double 
Blind 
Placebo 
Controlled 
123 18-
65 
Males and 
females 
meeting the 
DSM-IV 
criteria for 
MDD and had 
an IDS-SR30 
score greater 
than or equal to 
18 
Psychotic d/o, bipolar, 
OCD, PTSD, eating 
d/o, substance abuse, 
suicidal, diabetes, AI, 
CVD, HTN, 
neurodegenerative, 
fibromyalgia, asthma, 
currently pregnant, 
breastfeeding, 
infection/illness in the 
last month, coag d/o 
186 High dose and low 
dose curcumin (250 
mg and 500 mg) 
 
and 
 
saffron/curcumin 
combination (250 
mg of curcumin and 
15 mg of saffron) 
 
Sanmukhani 
et al2 
(2013) 
Randomized 
Controlled 
Trial 
45 >18 psychiatry 
outpatients of 
Sir Takhatsinhji 
General 
Hospital in 
Gujarat India. 
Individuals 
scored >7 on 
Hamilton 
Depression 
Scale 
suicidal, 
schizophrenic, 
schizoaffective, or 
other psychotic 
disorders, mental 
retardation, cognitive 
impairment, bipolar 
disorder. Abnormal lab 
tests, h/o seizure, 
thyroid disorder, 
allergy, failed at least 2 
adequate 
antidepressant 
therapies or taken any 
antidepressant in the 
last 30 days, or are 
currently receiving 
psychotherapy 
15 500 mg curcumin 
BID 
 
and  
 
curcumin/fluoxetine 
combo 
(500 mg curcumin 
+ 20 mg fluoxetine) 
 
Lopresti, 
Maes et al1 
(2014) 
Randomized 
double-blind 
placebo 
controlled 
study 
52 18-
65 
DSM-IV criteria 
for current 
major 
depressive 
disorder and 
(IDS-SR30) 
score ≥14. 
 
psychotic d/o, bipolar, 
OCD, PTSD, eating 
d/o, substance abuse, 
high risk of suicide, 
diabetics, AI diseases, 
CVD, HTN, 
neurodegenerative 
disorders, 
fibromyalgia, asthma, 
smokers, pregnant, had 
suffered an illness in 
past month, any 
coagulation disorder 
25 Curcumin 500mg 
BID 
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OUTCOMES MEASURED 
 All outcomes measured were POEMs and reflected the efficacy of curcumin on MDD 
symptoms. All three RTCs used self-rating tools in which the patients are asked to rate their 
depressive symptoms based on the DSM-IV criteria for major depressive episode (inability to 
sleep, sexual dysfunction, loss of interest in activities, self-esteem, etc.) In Lopresti, Drummond, 
outcomes were measured using IDS-SR30 score and STAI tool.3 In Sanmukhani et al., outcomes 
were measured using the HAM-D17 scale, and Lopresti, Maes et al. used IDS-SR30 and STAI 
tool.2,1 All RTCs did a baseline analysis using the self-rated tools as well as reanalyzed at various 
times throughout the study. 
 
RESULTS 
 In Lopresti, Maes et al., seventy-seven people were initially screened for the study and 
fifty-six met the criteria to join. A placebo and curcumin treatment group were created with 
twenty-eight individuals in each. Fifty-two people ultimately completed 8 weeks – 4 dropped 
out, one from the placebo and three from the curcumin group. Over the 8 weeks, 500mg 
curcumin capsules were given BID to the treatment group, and an identical looking pill 
containing cellulose was given to the placebo group. This review will focus on IDS-SR30 score 
between weeks 4 and 8. There was a significant change in IDS-SR30 score between weeks 4 and 
8 for those receiving the curcumin treatment, p=0.045. Between these weeks, ANOVA F score 
was 4.22, which is a large treatment effect due to statistical significance. Additional ANOVA 
analyses revealed that IDS-SR30 scores improved in both the placebo and treatment group in the 
first 4 weeks, but only continued to improve during the last 4 weeks in the treatment group. 
There were no significant changes in STAI scores over the full 8 weeks (baseline-week 4, 
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p=0.516; week 4-week 8, p=0.097; baseline-week 8, p=0.358). Adverse events were monitored 
and there were no significant differences between the placebo and treatment group, as shown in 
Table 2.1  
 
Table 2- List and frequency of adverse events reported by participants.1 
Complaint Curcumin Placebo 
No adverse events 16 14 
Digestive: bloating, nausea, 
diarrhea 
7 6 
Respiratory- breathing 
problems 
0 1 
Dermatology- dry skin, 
flaking skin 
3 2 
Neurology- headaches, 
dizziness 
2 2 
Pain- joint pain, back pain, 
neck pain 
2 4 
Cardiovascular- racing 
heart, chest pain 
2 0 
Vision- sore eyes, dry eyes, 
blurry vision 
3 0 
Auditory- ringing in ears 1 2 
Oral- dry mouth, sore gums 2 2 
 
Sanmukhani et al. did a 3-armed study and compared 500 mg BID of curcumin, 20 mg 
Fluoxetine, and 20mg Fluoxetine + 500 mg BID curcumin. Sixty patients were split with 20 
patients in each group. Forty-five patients completed the full 6 weeks. At the end of the study, 
the number of patients who responded to treatment (response is defined as 50% reduction in 
HAM-D17 scores compared to baseline) in the fluoxetine + curcumin group was 77.8% compared 
to the fluoxetine group of 64.7%.2 Table 3 summarizes these statistics. The numbers needed to 
treat (NNT) value is 8, meaning that for every 8 patients with MDD being treated with 20mg of 
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fluoxetine + 500 mg BID of curcumin, 1 more patient will have an improvement in their 
depressive symptoms compared to fluoxetine alone. This study also evaluated treatment 
emergent adverse events (TEAEs) to prove safety of curcumin. The most common adverse event 
recorded was gastritis, which was reported in all three groups studied. All TEAEs were mild and 
all medications were very well tolerated.2 
 
Table 3- Comparison between combination group and fluoxetine alone.2 
Control 
event rate 
(CER) 
Experimental 
event rate 
(EER) 
Relative 
benefit 
increase 
(RBI) 
Absolute 
benefit 
increase 
(ABI) 
Number 
needed to 
treat (NNT) 
95% CI; p 
value 
0.647 0.778 0.202 0.131 8 0.58 
 
Lopresti and Drummond did a four-arm study comparing high dose curcumin (500 mg), 
low dose curcumin (250 mg), low dose curcumin + saffron, and placebo. 33 patients were placed 
in the high dose curcumin, 28 in the low dose curcumin, 26 in low dose curcumin + saffron, and 
36 in placebo (n=123). All were placed on placebo for a week prior to being divided into 
treatment groups. Ultimately, 49 people were dropped from the study, leaving a total of 111 
participants who completing the full 12 weeks. This review will focus on IDS scores. There was 
a significant reduction in scores in all groups, except scores only decreased in the first 4 weeks in 
the placebo group. When comparing all active treatment groups to placebo, there was a 
significant change in IDS score from baseline to 12 weeks, p=0.031.3 Direct comparison of IDS 
response rates of high dose curcumin and placebo is seen in Table 4. The NNT value is 7, 
meaning that for every 7 patients with MDD being treated with 500 mg curcumin, 1 more patient 
will have an improvement in their depressive symptoms compared to placebo. Lopresti and 
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Drummond also analyzed adverse events. The high dose curcumin group reported the most 
adverse events, although there were of minor severity. The most common complaint was 
diarrhea and spicy aftertaste.3  
 
Table 4- Comparison between high dose curcumin and placebo.3   
Control 
event rate 
(CER) 
 
Experiment 
event rate 
(EER) 
 
Relative 
benefit 
increase (RBI) 
Absolute 
benefit 
increase 
(ABI) 
Number needed 
to treat (NNT) 
0.13 0.28 1.15 0.15 7 
 
 
DISCUSSION 
Two out of the three RCTs incorporated in this paper showed a statistically significant 
decrease in depression symptoms in patients suffering from MDD who were treated with 
curcumin. Additionally, all three RCTs found that curcumin was a safe intervention with minor 
adverse events. Other studies that were done on animal models proved it to be safe even at supra-
therapeutic doses.2 Curcumin is widely available in the United States and does not require a 
prescription. The most common method is one to three capsules of 500 mg.6 It is often used as a 
natural supplement for ulcers, analgesic effects, and to relieve flatulence.6 However, because of 
the widespread availability of curcumin, it is difficult to assess the purity and composition of the 
capsules being sold. Consequently, the bioavailability of these products is questionable. 
Additionally, curcumin is not FDA approved to attest to its efficacy and safety. Therefore, 
efficacy and safety is limited to a few clinical trials and it is challenging to determine interaction 
with other medications or health conditions. Contraindications to use include allergies, 
pregnancy, breast feeding, and those with gallstones or bile duct obstructions.6   
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 Weaknesses of all three RCTs were small sample sizes, which limits the reliability of the 
findings. Lopresti, Maes et al. and Sanmukhani et al. both had less than 100 participants. 
Additionally, Sanmukhani et al. and Lopresti, Drummond had losses to follow-up greater than 
20%, meaning that all subjects who entered the trial were not accounted for and attributed at its 
conclusion. Sanmukhani et al. also did not use a placebo and also did not have a double-blind 
study.  
Other limitations of this analysis are the lack of RCTs that evaluate the effects of 
curcumin on humans. There are many trials of curcumin results on other animals, such as rats, 
but very little on humans. Therefore, the search was limited and only included the three RCTs 
that existed and met all inclusion criteria. Two out of the three studies were by the same research 
group which limited the diversity and methods used to analyze treatment effect. Lastly, since the 
studies only showed significant data after several weeks of treatment, a longer follow up time is 
needed to evaluate the full effects of curcumin. Future studies should include a larger patient 
population as well as longer follow up time.  
 
CONCLUSIONS 
These three chosen studies show that curcumin is a safe and effective treatment option for 
patients who suffer from MDD. No serious life-threatening reports were made during the trials 
and there is evidence to show that curcumin is safe at supra-therapeutic doses even up to 8 
g/day.2  
The evaluation of holistic medication on MDD is still underway and the research is still 
fairly new.  Due to the limited amount of studies and small sample sizes, more studies must be 
done to further compare curcumin to other drugs as well as evaluate it over a longer time. Since 
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curcumin is a natural spice and not FDA approved, it is imperative to confirm its all-around 
safety, especially when taken with other drugs for unrelated diseases. Many patients who suffer 
from depression have other coexisting medical diagnoses and may be taking other medications. 
In order to fully establish curcumin as safe monotherapy for MDD, future studies should include 
drug interactions with other common medications.  
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